Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Moderna Files Spikevax as Booster for Kids Aged 6 Months to 4 Years
July 1, 2024
- Daiichi Sankyo’s ADC Arbitration Win Finalized with No Appeal
July 1, 2024
- Healios Pushes Back Definitive MultiStem Deal with Nobelpharma
July 1, 2024
- Xocova Slashes Risk of Hospitalization in Real-World Setting
July 1, 2024
- EA Pharma Grants Global Rights to IBD Drugs to Ensho
July 1, 2024
- Pfizer, Viatris to Copromote Cibinqo, Litfulo in Japan
July 1, 2024
- Kyowa Kirin Files Pen Version of Lumicef in Japan
July 1, 2024
- Eisai’s Alzheimer’s Med Leqembi Now Available in China
July 1, 2024
- Pfizer Seeks Japan Approval for Ulcerative Colitis Drug
July 1, 2024
- Pfizer Files Hemophilia B Gene Therapy in Japan
July 1, 2024
- Physician Predicts 30-40% Switch Rate for Chugai’s PNH Drug Piasky
June 28, 2024
- Nxera Snags US$10 Million Milestone from AbbVie in Neurology Collab
June 28, 2024
- FDA Snubs Daiichi Sankyo’s HER3 ADC over Third-Party Manufacturing Issue
June 28, 2024
- Takeda Files Alagille Syndrome Drug Maralixibat in Japan
June 28, 2024
- Ayumi Taps Ex-Ferring Japan CEO as New President
June 28, 2024
- Sumitomo Resolved to Revive Business, Optimize Japan Organization: New CEO
June 27, 2024
- Jugo Tsumura to Step Down as Ferring Japan CEO
June 27, 2024
- Takeda Targets 50% Female Ratio for Board of Directors: CEO
June 27, 2024
- Takeda CEO’s Pay Tops 2 Billion Yen in FY2023
June 27, 2024
- TGCV Drug CNT-01 Misses Goal in Japan PIIb/III Study: Toa Eiyo
June 26, 2024
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…